Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplivanserin in sleep maintenance insomnia
NCT00253903Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2005
- Primary completion
- Nov 2007
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in Sleep initiation and maintenance disorder comparing Eplivanserin with Placebo (2 arms). Primary endpoint: Patient-reported Wake Time After Sleep Onset at 12 weeks. Started Nov 2005; status: completed.
02
Drugs
eplivanserin
03
Conditions
Sleep initiation and maintenance disorder
Beyond the preview
Go deeper on NCT00253903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00253903.